| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Author index
|
|
|
2003
|
41 |
S3 |
p. S121-S122
2 p.
|
artikel
|
| 2 |
E-41. A clinicopathological study of resected adenocarcinoma less than 2 cm in size
|
Ikeda, Norihiko
|
|
2003
|
41 |
S3 |
p. S51-
1 p.
|
artikel
|
| 3 |
E-23. A DNA methylation profile of lung cancer
|
Esteller, Manel
|
|
2003
|
41 |
S3 |
p. S30-
1 p.
|
artikel
|
| 4 |
E-54. Alternative therapy plus conventional therapy: The science behind art or the art behind science
|
Mok, Tony S.K.
|
|
2003
|
41 |
S3 |
p. S69-
1 p.
|
artikel
|
| 5 |
E-68. Are new cytotoxic agents worth investigating?
|
Scagliotti, Giorgio V.
|
|
2003
|
41 |
S3 |
p. S84-S85
2 p.
|
artikel
|
| 6 |
E-61. Assessment and management of fatigue in lung cancer
|
Pirker, Robert
|
|
2003
|
41 |
S3 |
p. S77-
1 p.
|
artikel
|
| 7 |
E-64. Bcl-2 as a target in lung cancer
|
Rudin, Charles M.
|
|
2003
|
41 |
S3 |
p. S80-
1 p.
|
artikel
|
| 8 |
E-1.Cancer management & clinical research in developing countries
|
Abratt, Raymond P.
|
|
2003
|
41 |
S3 |
p. S3-S4
2 p.
|
artikel
|
| 9 |
E-40. Chemoprevention of lung cancer: Challenges in the 21st century. Genetics, risk modeling, and molecular targets
|
Hong, Waun Ki
|
|
2003
|
41 |
S3 |
p. S50-
1 p.
|
artikel
|
| 10 |
E-10. Chemoradiation for stage III non-small cell lung cancer
|
Bonomi, Philip
|
|
2003
|
41 |
S3 |
p. S14-
1 p.
|
artikel
|
| 11 |
E-55. Chemoradiation of stage III NSCLC
|
Mornex, Francoise
|
|
2003
|
41 |
S3 |
p. S70-
1 p.
|
artikel
|
| 12 |
E-20. Chemotherapy for advanced NSCLC in PS2 patients
|
Cullen, Michael
|
|
2003
|
41 |
S3 |
p. S27-
1 p.
|
artikel
|
| 13 |
E-34. Chemotherapy for non-small cell lung cancer in the elderly
|
Gridelli, Cesare
|
|
2003
|
41 |
S3 |
p. S43-S44
2 p.
|
artikel
|
| 14 |
E-66. Clinical experience with Tarceva™
|
Sandier, Alan B.
|
|
2003
|
41 |
S3 |
p. S82-
1 p.
|
artikel
|
| 15 |
E-47. Combined modality therapy in older patients with stage III NSCLC and limited SCLC
|
Langer, Corey J.
|
|
2003
|
41 |
S3 |
p. S57-S60
4 p.
|
artikel
|
| 16 |
E-88. Combined modality therapy of limited stage SCLC
|
Wagner, Henry
|
|
2003
|
41 |
S3 |
p. S107-
1 p.
|
artikel
|
| 17 |
E-21. Cyclooxygenase-2-dependent regulation of the malignant phenotype in non-small cell lung cancer
|
Dubinett, Steven M.
|
|
2003
|
41 |
S3 |
p. S28-
1 p.
|
artikel
|
| 18 |
E-87.Early detection and chemoprevention of lung cancer
|
Zandwijk, Nico van
|
|
2003
|
41 |
S3 |
p. S106-
1 p.
|
artikel
|
| 19 |
E-25. Effective treatments for smoking: Established and experimental approaches
|
Fagerstrom, Karl
|
|
2003
|
41 |
S3 |
p. S32-
1 p.
|
artikel
|
| 20 |
E-5. Encouraging informed patients: Towards joint decision making
|
Baird, Jesme
|
|
2003
|
41 |
S3 |
p. S8-
1 p.
|
artikel
|
| 21 |
E-80.Enhancing communication in the lung cancer consultation
|
Tattersall, Martin
|
|
2003
|
41 |
S3 |
p. S99-
1 p.
|
artikel
|
| 22 |
E-67. Epidemiology and molecular epidemiology of lung cancer in men and women
|
Santella, Regina M.
|
|
2003
|
41 |
S3 |
p. S83-
1 p.
|
artikel
|
| 23 |
E-29. Epidermal growth factor receptor tyrosine kinase inhibitors: Single agent therapy
|
Fukuoka, Masahiro
|
|
2003
|
41 |
S3 |
p. S38-
1 p.
|
artikel
|
| 24 |
E-8. Evidence-based palliative radiotherapy
|
Bezjak, Andrea
|
|
2003
|
41 |
S3 |
p. S12-
1 p.
|
artikel
|
| 25 |
E-32. Global tobacco policy
|
Gray, Nigel
|
|
2003
|
41 |
S3 |
p. S41-
1 p.
|
artikel
|
| 26 |
E-53. Helical tomotherapy: An innovative technological radiation therapeutic approach for lung cancer
|
Mehta, Minesh
|
|
2003
|
41 |
S3 |
p. S67-S68
2 p.
|
artikel
|
| 27 |
E-82. High-grade neuroendocrine (NE) tumors: What we know and important unanswered questions
|
Travis, William D.
|
|
2003
|
41 |
S3 |
p. S101-
1 p.
|
artikel
|
| 28 |
E-38. Historical milestones in small cell lung cancer
|
Hansen, Heine H.
|
|
2003
|
41 |
S3 |
p. S48-
1 p.
|
artikel
|
| 29 |
E-73.Hormones - do they make a difference in lung cancer?
|
Siegfried, Jill M.
|
|
2003
|
41 |
S3 |
p. S91-
1 p.
|
artikel
|
| 30 |
E-76.Identifying the high risk subject: Assessment of DNA damage and repair
|
Spitz, Margaret R.
|
|
2003
|
41 |
S3 |
p. S95-
1 p.
|
artikel
|
| 31 |
E-15. Imaging hypoxic micro-regions of lung cancers
|
Chapman, J.D.
|
|
2003
|
41 |
S3 |
p. S21-S22
2 p.
|
artikel
|
| 32 |
E-9. Improving lung cancer outcomes: Patient perspective
|
Blum, Diane
|
|
2003
|
41 |
S3 |
p. S13-
1 p.
|
artikel
|
| 33 |
E-59. Improving lung cancer outcomes: Physician perspective
|
Peters, Matthew
|
|
2003
|
41 |
S3 |
p. S75-
1 p.
|
artikel
|
| 34 |
E-17. Improving the therapeutic index of radiosensitizers
|
Choy, Hak
|
|
2003
|
41 |
S3 |
p. S24-
1 p.
|
artikel
|
| 35 |
E-69. Influential papers since the last IASLC Conference: Cytotoxic therapy
|
Schiller, Joan H.
|
|
2003
|
41 |
S3 |
p. S86-S87
2 p.
|
artikel
|
| 36 |
E-2. Inhibitors of MAP kinases
|
Adjei, Alex A.
|
|
2003
|
41 |
S3 |
p. S5-
1 p.
|
artikel
|
| 37 |
E-7. Inluential radiotherapy papers published since the last IASLC conference
|
Ball, David
|
|
2003
|
41 |
S3 |
p. S10-S11
2 p.
|
artikel
|
| 38 |
E-37. Integrated genomic and proteomics-based approaches to lung cancer profiling
|
Hanash, Sam
|
|
2003
|
41 |
S3 |
p. S47-
1 p.
|
artikel
|
| 39 |
E-48. Is adjuvant chemotherapy a part of the curative treatment of operable non-small cell lung cancer?
|
Le Chevalier, Thierry
|
|
2003
|
41 |
S3 |
p. S61-
1 p.
|
artikel
|
| 40 |
E-86.Is there still a role for mediastinoscopy?
|
Urschel, John
|
|
2003
|
41 |
S3 |
p. S105-
1 p.
|
artikel
|
| 41 |
E-36. Long-term results after vertebral body resections for non-small cell lung cancer
|
Grunenwald, Dominique H.
|
|
2003
|
41 |
S3 |
p. S46-
1 p.
|
artikel
|
| 42 |
E-84.Long-term results of surgical intervention of T4 tumors: left atrium and/or great vessels
|
Tsuchiya, Ryosuke
|
|
2003
|
41 |
S3 |
p. S103-
1 p.
|
artikel
|
| 43 |
E-91. Long-term results of surgical intervention of T4 tumors resection of carcinomatous pleural disease
|
Yokoi, Kohei
|
|
2003
|
41 |
S3 |
p. S110-
1 p.
|
artikel
|
| 44 |
E-19. Lung cancer clinical trials: Principles and pitfalls
|
Crowley, John J.
|
|
2003
|
41 |
S3 |
p. S26-
1 p.
|
artikel
|
| 45 |
E-6. Lung cancer in the older person
|
Balducci, Lordovico
|
|
2003
|
41 |
S3 |
p. S9-
1 p.
|
artikel
|
| 46 |
E-16. Molecular and cytogenetic alterations in Chinese non-small cell lung cancer
|
Cheng, Shujun
|
|
2003
|
41 |
S3 |
p. S23-
1 p.
|
artikel
|
| 47 |
E-26. Molecular markers in early detection
|
Field, John K.
|
|
2003
|
41 |
S3 |
p. S33-S34
2 p.
|
artikel
|
| 48 |
E-12. Molecular pathology of neuroendocrine lung tumors
|
Brambilla, Elisabeth
|
|
2003
|
41 |
S3 |
p. S16-S17
2 p.
|
artikel
|
| 49 |
E-90. Molecular pathology of small cell lung cancer
|
Wistuba, Ignacio I.
|
|
2003
|
41 |
S3 |
p. S109-
1 p.
|
artikel
|
| 50 |
E-60. Molecular profiling of non-small cell lung cancer
|
Petersen, Iver
|
|
2003
|
41 |
S3 |
p. S76-
1 p.
|
artikel
|
| 51 |
E-79.Molecular targets for prevention of lung cancer
|
Szabo, Eva
|
|
2003
|
41 |
S3 |
p. S98-
1 p.
|
artikel
|
| 52 |
E-43. Most influential papers in surgery
|
Johnston, Michael R.
|
|
2003
|
41 |
S3 |
p. S53-
1 p.
|
artikel
|
| 53 |
E-56. Multimodality approaches for malignant pleural mesothelioma
|
Pass, Harvey I.
|
|
2003
|
41 |
S3 |
p. S71-
1 p.
|
artikel
|
| 54 |
E-65. Neuroendocrine tumors of the lung
|
Salgia, Ravi
|
|
2003
|
41 |
S3 |
p. S81-
1 p.
|
artikel
|
| 55 |
E-78.New bronchoscopic interventions
|
Sutedja, Tom G.
|
|
2003
|
41 |
S3 |
p. S97-
1 p.
|
artikel
|
| 56 |
E-63. New gene targets for lung cancer therapy
|
Roth, Jack A.
|
|
2003
|
41 |
S3 |
p. S79-
1 p.
|
artikel
|
| 57 |
E-75.Optimal number of cytotoxic agents and chemotherapy cycles for advanced NSCLC
|
Socinski, Mark A.
|
|
2003
|
41 |
S3 |
p. S93-S94
2 p.
|
artikel
|
| 58 |
E-83. Outpatient management of malignant pleural effusions
|
Tremblay, Alain
|
|
2003
|
41 |
S3 |
p. S102-
1 p.
|
artikel
|
| 59 |
E-27. Overview: Impact of microarray technology on lung cancer classification and biomarker development
|
Franklin, Wilbur A.
|
|
2003
|
41 |
S3 |
p. S35-S36
2 p.
|
artikel
|
| 60 |
E-11. PET scanning for operable non-small cell lung cancer
|
Boyer, Michael J.
|
|
2003
|
41 |
S3 |
p. S15-
1 p.
|
artikel
|
| 61 |
E-62. Pharmacogenomics: Individualized therapy
|
Rosell, Rafael
|
|
2003
|
41 |
S3 |
p. S78-
1 p.
|
artikel
|
| 62 |
E-46. Phase II trials of promising chemopreventive agents
|
Lam, Stephen
|
|
2003
|
41 |
S3 |
p. S56-
1 p.
|
artikel
|
| 63 |
E-28. Placing lung cancer on the global health care agenda: The global lung cancer coalition
|
Freiheit, Deirdre
|
|
2003
|
41 |
S3 |
p. S37-
1 p.
|
artikel
|
| 64 |
E-3. Politicizing lung cancer: Mobilizing decision makers' support
|
Aldige, Carolyn
|
|
2003
|
41 |
S3 |
p. S6-
1 p.
|
artikel
|
| 65 |
E-85.Positron emission tomography (PET) and CT co-registration: incorporating functional and anatomical information in radiation treatment planning for lung cancer
|
Ung, Yee C.
|
|
2003
|
41 |
S3 |
p. S104-
1 p.
|
artikel
|
| 66 |
E-24. Practice guidelines: Do they matter? Do they work?
|
Evans, William K.
|
|
2003
|
41 |
S3 |
p. S31-
1 p.
|
artikel
|
| 67 |
E-89. Pre-operative chemotherapy for stage I to III NSCLC
|
Westeel, Virginie
|
|
2003
|
41 |
S3 |
p. S108-
1 p.
|
artikel
|
| 68 |
E-33. Prevention and management of brain metatsases
|
Gregor, Anna
|
|
2003
|
41 |
S3 |
p. S42-
1 p.
|
artikel
|
| 69 |
E-18. Problems in the pathologic diagnosis of malignant mesothelioma
|
Churg, Andrew
|
|
2003
|
41 |
S3 |
p. S25-
1 p.
|
artikel
|
| 70 |
E-74. Pulmonary neuroendocrine tumors: Incidence and prognosis of histological subtypes. A population-based study in Denmark
|
Skuladottir, Halla
|
|
2003
|
41 |
S3 |
p. S92-
1 p.
|
artikel
|
| 71 |
E-71.Radiation oncology research priorities in the management of small cell lung cancer
|
Sheehan, Finbarr
|
|
2003
|
41 |
S3 |
p. S89-
1 p.
|
artikel
|
| 72 |
E-4. Radiation therapy of lung cancer detected by screening
|
Armstrong, John G.
|
|
2003
|
41 |
S3 |
p. S7-
1 p.
|
artikel
|
| 73 |
E-50. Radiofrequency ablation
|
Luketich, James D.
|
|
2003
|
41 |
S3 |
p. S63-
1 p.
|
artikel
|
| 74 |
E-52. Role of PET in assessing response to radical chemoradiation
|
Mac Manus, Michael P.
|
|
2003
|
41 |
S3 |
p. S65-S66
2 p.
|
artikel
|
| 75 |
E-42. Screening and early detection of lung cancer
|
Jett, James R.
|
|
2003
|
41 |
S3 |
p. S52-
1 p.
|
artikel
|
| 76 |
E-58. Screening for lung cancer
|
Patz Jr., Edward F.
|
|
2003
|
41 |
S3 |
p. S73-S74
2 p.
|
artikel
|
| 77 |
E-22. Should surgery (S) be reconsidered for limited small-cell lung cancer (LD-SCLC)?
|
Eberhardt, Wilfried
|
|
2003
|
41 |
S3 |
p. S29-
1 p.
|
artikel
|
| 78 |
E-45. Small cell lung cancer: Targeting minimal residual disease
|
Krug, Lee M.
|
|
2003
|
41 |
S3 |
p. S55-
1 p.
|
artikel
|
| 79 |
E-81.Small cell lung cancer- treatment strategies in the elderly and poor performance status patients
|
Thatcher, N.
|
|
2003
|
41 |
S3 |
p. S100-
1 p.
|
artikel
|
| 80 |
E-35. Smoking and the sexes
|
Gritz, Ellen R.
|
|
2003
|
41 |
S3 |
p. S45-
1 p.
|
artikel
|
| 81 |
E-39. Standardization of biomarkers for chemoprevention studies in lung cancer
|
Hirsch, Fred R.
|
|
2003
|
41 |
S3 |
p. S49-
1 p.
|
artikel
|
| 82 |
E-72.Statistical strategies for analyzing the microarray data in human lung cancer
|
Shyr, Yu
|
|
2003
|
41 |
S3 |
p. S90-
1 p.
|
artikel
|
| 83 |
E-57. Surgical approach to neuroendocrine tumors
|
Passlick, Berward
|
|
2003
|
41 |
S3 |
p. S72-
1 p.
|
artikel
|
| 84 |
E-44. Systemic therapy for mesothelioma: Old and new
|
Kindler, Hedy Lee
|
|
2003
|
41 |
S3 |
p. S54-
1 p.
|
artikel
|
| 85 |
E-70. Telomerase in lung cancer
|
Shay, J.W.
|
|
2003
|
41 |
S3 |
p. S88-
1 p.
|
artikel
|
| 86 |
E-30. The hallmarks of lung cancer
|
Gazdar, Adi F.
|
|
2003
|
41 |
S3 |
p. S39-
1 p.
|
artikel
|
| 87 |
E-31. The IASLC staging revision project
|
Goldstraw, Peter
|
|
2003
|
41 |
S3 |
p. S40-
1 p.
|
artikel
|
| 88 |
E-77.The need for a world strategy for clinical trials
|
Stephens, Richard
|
|
2003
|
41 |
S3 |
p. S96-
1 p.
|
artikel
|
| 89 |
E-13. The risks of modern cigarettes
|
Burns, David M.
|
|
2003
|
41 |
S3 |
p. S18-S19
2 p.
|
artikel
|
| 90 |
E-51. The work of the cochrane collaboration lung cancer review group
|
Macbeth, Fergus
|
|
2003
|
41 |
S3 |
p. S64-
1 p.
|
artikel
|
| 91 |
E-49. Treatment of cancer anorexia/cachexia
|
Loprinzi, Charles L.
|
|
2003
|
41 |
S3 |
p. S62-
1 p.
|
artikel
|
| 92 |
E-14. Tumor proteomic patterns predict classification and tumor behavior in human non-small cell lung cancer
|
Yanagisawa, Kiyoshi
|
|
2003
|
41 |
S3 |
p. S20-
1 p.
|
artikel
|
| 93 |
I-99. A phase II efficacy study of brostallicin, a novel minor groove binder (MGB), in patients with platinum refractory or resistant non-small cell lung cancer (NSCLC)
|
Sandler, A.
|
|
2003
|
41 |
S3 |
p. S118-
1 p.
|
artikel
|
| 94 |
I-100. Candidate predictive and surrogate markers of antitumor activity with Tarceva™
|
Soulières, Denis
|
|
2003
|
41 |
S3 |
p. S119-
1 p.
|
artikel
|
| 95 |
I-97. Clinical benefit in NSCLC: The evidence for Gefitinib (“Iressa”)
|
Lynch, Thomas
|
|
2003
|
41 |
S3 |
p. S116-
1 p.
|
artikel
|
| 96 |
I-93. Gefitinib (“Iressa”): The patients' experience
|
Goss, Glen
|
|
2003
|
41 |
S3 |
p. S112-
1 p.
|
artikel
|
| 97 |
I-101. Novel approaches in oncology
|
Wheeler, Catherine
|
|
2003
|
41 |
S3 |
p. S120-
1 p.
|
artikel
|
| 98 |
I-94. Symptoms and quality of life: Important patient outcomes?
|
Harper, Peter
|
|
2003
|
41 |
S3 |
p. S113-
1 p.
|
artikel
|
| 99 |
I-96. Tarceva™: A potent HER1/EGFR-tyrosine kinase inhibitor
|
Hidalgo, Manuel
|
|
2003
|
41 |
S3 |
p. S115-
1 p.
|
artikel
|
| 100 |
I-98. Tarceva™-associated rash to maximize treatment outcome?
|
Pérez-Soler, Romàn
|
|
2003
|
41 |
S3 |
p. S117-
1 p.
|
artikel
|
| 101 |
I-92. Targeting HER1/EGFR to improve outcomes for patients with NSCLC
|
Gatzemeier, Ulrich
|
|
2003
|
41 |
S3 |
p. S111-
1 p.
|
artikel
|
| 102 |
I-95. Targeting the EGFR: Prognostic and clinical implications
|
Herbst, Roy S.
|
|
2003
|
41 |
S3 |
p. S114-
1 p.
|
artikel
|
Tijdschrift beschrijving